Alkermes plc (ALKS) Announces Completion of Patient Enrollment in Pivotal Phase 3 Study of Aripiprazole Lauroxil
10/8/2013 10:03:22 AM
DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today announced completion of patient enrollment in the pivotal, multinational phase 3 study evaluating aripiprazole lauroxil in patients with schizophrenia. Aripiprazole lauroxil is designed to provide patients with once-monthly dosing of a medication that, once in the body, converts into aripiprazole, a molecule that is commercially available under the name ABILIFY®. Alkermes continues to expect topline results from the phase 3 study in the first half of 2014.
Help employers find you! Check out all the jobs and post your resume.